| Similar Articles |
|---|
 |
The Motley Fool
June 21, 2007
Brian Lawler |
Panacos Validates Itself Panacos releases more clinical trial results for an exciting drug. Investors, take note.   |
The Motley Fool
May 3, 2007
Brian Lawler |
Panacos Reveals the Plan The drug developer details the plan for clinical testing of its lead compound and announced its first-quarter financials. Investors, take note. |
The Motley Fool
March 13, 2007
Brian Lawler |
Panacos Springs Ahead Panacos advances its lead drug program. |
The Motley Fool
November 29, 2010
Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
The Motley Fool
August 24, 2005
Tarek Sultani |
Panacos Gives HIV Reason to Panic Panacos' new anti-retroviral PA-457 has huge implications for the company's future. The stock price soared 46% Monday, closing at $10.30. While this surge may seem enormous, it's only the tip of the iceberg if this drug proves as successful as these trials indicate. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Pharmaceutical Executive
December 1, 2005
Alana Klein |
Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance. |
BusinessWeek
September 12, 2005
John Carey |
A Better Way To Ambush AIDS? HIV increasingly outwits today's drugs even as side effects take a toll. But Panacos Pharmaceuticals' experimental drug opens the door to a new line of attack. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
The Motley Fool
March 28, 2008
Brian Lawler |
Pfizer Gets the Signal to Steal Pfizer's acquisition of Encysive Pharmaceuticals is set for Monday. |
American Journal of Nursing
March 2010
David E. Vance |
Aging with HIV: Clinical Considerations for an Emerging Population Since the advent of highly active antiretroviral therapy, HIV infection has become a chronic, albeit life-threatening, condition that can be managed; therefore, more and more people are growing older with HIV. |
American Journal of Nursing
March 2010
Bradley-Springer et al. |
Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV. |
